68 research outputs found
ΠΠΎΠΏΠΈΠ½Π³-ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ ΠΈ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊ Π·Π΄ΠΎΡΠΎΠ²ΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ
Highlights. The importance of psychological assessment and psychological support in Cardiology Departments has been demonstrated. For the first time, predominant coping strategy in cardiac patients was revealed.Background. Why do patients with the same disease, disease course, prognosis and treatment have different outcomes? One hypothesis points to the influence of internal resources used in coping with the disease. A.B. Smulewicz in 1984 identified the association between the clinical symptoms and mental state of the patient.Aim. To determine characteristics of coping behavior and attitude toward health in cardiac patients from Surgical and Therapeutic Departments.Methods. 122 patients admitted to the State Autonomous Healthcare Institution βN.A. Semashko Republican Clinical Hospitalβ were included in the study. The 1st group consisted of in-patients from the Department of Surgical Treatment of Heart Rhythm Disorders and Electrical Cardiac Stimulation (61 patients); the 2nd group consisted of patients from the 1st Cardiology Department (61 patients). A questionnaire developed by R. Lazarus and S. Falkman in 1988 was used to determine coping strategies, and a questionnaire developed by R. A. Berezovskaya in 2005 was used to assess attitudes towards health.Results. Active coping strategy predominates in surgical patients, and distancing and avoidant strategies predominate in therapeutic patients. Correlation between characteristics of coping strategy and attitudes toward health was analyzed: active coping strategies are accompanied by high behavioral, cognitive, and emotional aspects. An inverse correlation is noted in distancing and avoidant coping strategies.Conclusion. Psychological comfort and correct attitude of patient to his/her disease is an important part of rehabilitation that highlights the significance of psychometric testing in cardiac patients.ΠΡΠ½ΠΎΠ²Π½ΡΠ΅ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ. ΠΠΎΠΊΠ°Π·Π°Π½Π° Π²Π°ΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΊΡΠΈΠ½ΠΈΠ½Π³ΠΎΠ² ΠΈ ΡΡΠ°ΡΠ½ΠΎΠΉ ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠΎΠΌΠΎΡΠΈ Π² ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡΡ
. ΠΠΏΠ΅ΡΠ²ΡΠ΅ Π²ΡΡΠ²Π»Π΅Π½ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°ΡΡΠΈΠΉ ΠΊΠΎΠΏΠΈΠ½Π³ Ρ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ.ΠΠΊΡΡΠ°Π»ΡΠ½ΠΎΡΡΡ. ΠΠ΄Π½ΠΎΠΉ ΠΈΠ· Π³ΠΈΠΏΠΎΡΠ΅Π·, ΠΎΠ±ΡΡΡΠ½ΡΡΡΠΈΡ
, ΠΏΠΎΡΠ΅ΠΌΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ Ρ ΠΎΠ΄ΠΈΠ½Π°ΠΊΠΎΠ²ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ, ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ, ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ ΠΈ ΡΡΠ»ΠΎΠ²ΠΈΡΠΌΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΠΌΠ΅ΡΡ ΡΠ°Π·Π½ΡΠΉ ΠΈΡΡ
ΠΎΠ΄, ΡΠ²Π»ΡΠ΅ΡΡΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π²Π½ΡΡΡΠ΅Π½Π½ΠΈΡ
ΠΏΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ΅Π·Π΅ΡΠ²ΠΎΠ² Π² Π±ΠΎΡΡΠ±Π΅ Ρ Π±ΠΎΠ»Π΅Π·Π½ΡΡ. ΠΡΠ΅ Π² 1984 Π³. Π.Π. Π‘ΠΌΡΠ»Π΅Π²ΠΈΡ Π²ΡΡΠ²ΠΈΠ» Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·Ρ ΡΠΎΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΈΠ½Π΄ΡΠΎΠΌΠ° ΠΈ ΠΏΡΠΈΡ
ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°.Π¦Π΅Π»Ρ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΠΎΠ³ΠΎ ΠΊΠΎΠΏΠΈΠ½Π³Π° ΠΈ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π·Π΄ΠΎΡΠΎΠ²ΡΡ Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈ ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΎΡΠ»ΠΈ 122 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΌΠ½ΠΎΠ³ΠΎΠΏΡΠΎΡΠΈΠ»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΡΠΏΡΠ±Π»ΠΈΠΊΠ°Π½ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠ³ΠΎ ΡΠ΅Π½ΡΡΠ° ΠΠΠ£Π Π Π Β«Π ΠΠ ΠΈΠΌΠ΅Π½ΠΈ Π.Π. Π‘Π΅ΠΌΠ°ΡΠΊΠΎΒ»: ΠΏΠ΅ΡΠ²ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π±ΠΎΠ»ΡΠ½ΡΠ΅, Π½Π°Ρ
ΠΎΠ΄ΠΈΠ²ΡΠΈΠ΅ΡΡ Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠΌ Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π² ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΈ Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ»ΠΎΠΆΠ½ΡΡ
Π½Π°ΡΡΡΠ΅Π½ΠΈΠΈΜ ΡΠΈΡΠΌΠ° ΡΠ΅ΡΠ΄ΡΠ° ΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΠΊΠ°ΡΠ΄ΠΈΠΎΡΡΠΈΠΌΡΠ»ΡΡΠΈΠΈ (61 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ); Π²ΡΠΎΡΡΡ Π³ΡΡΠΏΠΏΡ β ΠΏΠ°ΡΠΈΠ΅Π½ΡΡ 1-Π³ΠΎ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡ (61 ΡΠ΅Π»ΠΎΠ²Π΅ΠΊ). ΠΠ΅ΡΠΎΠ΄ΠΈΠΊΠ° ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΊΠΎΠΏΠΈΠ½Π³-ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΉ Π²ΠΊΠ»ΡΡΠ°Π»Π° ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ Π . ΠΠ°Π·Π°ΡΡΡΠ° ΠΈ Π‘. Π€ΠΎΠ»ΠΊΠΌΠ°Π½ 1988 Π³. Β«Π‘ΠΏΠΎΡΠΎΠ±Ρ ΡΠΎΠ²Π»Π°Π΄Π°ΡΡΠ΅Π³ΠΎ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡΒ». ΠΠ»Ρ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΊ Π·Π΄ΠΎΡΠΎΠ²ΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ ΠΎΠΏΡΠΎΡΠ½ΠΈΠΊ, ΡΠ°Π·ΡΠ°Π±ΠΎΡΠ°Π½Π½ΡΠΉ Π .Π. ΠΠ΅ΡΠ΅Π·ΠΎΠ²ΡΠΊΠΎΠΈΜ Π² 2005 Π³.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π£ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ
ΠΈΡΡΡΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ ΠΏΡΠ΅ΠΎΠ±Π»Π°Π΄Π°Π»Π° ΡΡΡΠ°ΡΠ΅Π³ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΡΡ
Π΄Π΅ΠΉΡΡΠ²ΠΈΠΉ, Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΡ β Π΄ΠΈΡΡΠ°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ Π±Π΅Π³ΡΡΠ²ΠΎ-ΠΈΠ·Π±Π΅Π³Π°Π½ΠΈΠ΅. ΠΡΠΌΠ΅ΡΠ΅Π½Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ ΠΌΠ΅ΠΆΠ΄Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ ΠΊΠΎΠΏΠΈΠ½Π³ΠΎΠΌ ΠΈ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ΠΌ ΠΊ Π·Π΄ΠΎΡΠΎΠ²ΡΡ: ΡΡΡΠ°ΡΠ΅Π³ΠΈΠΈ Π°ΠΊΡΠΈΠ²Π½ΡΡ
Π΄Π΅ΠΉΡΡΠ²ΠΈΠΉ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ Π²ΡΡΠΎΠΊΠΈΠΌ ΠΏΠΎΠ²Π΅Π΄Π΅Π½ΡΠ΅ΡΠΊΠΈΠΌ, ΠΊΠΎΠ³Π½ΠΈΡΠΈΠ²Π½ΡΠΌ ΠΈ ΡΠΌΠΎΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ Π°ΡΠΏΠ΅ΠΊΡΠ°ΠΌΠΈ. ΠΠ±ΡΠ°ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ Π²ΡΡΠ²Π»Π΅Π½Π° ΠΏΡΠΈ ΡΠΈΠΏΠ°Ρ
Π΄ΠΈΡΡΠ°Π½ΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π±Π΅Π³ΡΡΠ²Π°-ΠΈΠ·Π±Π΅Π³Π°Π½ΠΈΡ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΈΡ
ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΊΠΎΠΌΡΠΎΡΡ ΠΈ ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠ΅ ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° ΠΊ Π±ΠΎΠ»Π΅Π·Π½ΠΈ ΡΠ»ΡΠΆΠΈΡ Π²Π°ΠΆΠ½ΡΠΌ ΡΡΠ°ΠΏΠΎΠΌ ΡΠ΅Π°Π±ΠΈΠ»ΠΈΡΠ°ΡΠΈΠΈ, ΡΡΠΎ ΠΏΠΎΠ΄ΡΠ²Π΅ΡΠΆΠ΄Π°Π΅Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΏΡΠΈΡ
ΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³Π° Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠΈΠ»Ρ. ΠΠ»Ρ ΡΠΊΡΠΈΠ½ΠΈΠ½Π³-ΡΠ΅ΡΡΠΎΠ² ΠΈ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΠΊΠΎΡΡΠ΅ΠΊΡΠΈΠΈ ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ Π² ΡΠ°Π±ΠΎΡΡ ΠΊΠ°ΡΠ΄ΠΈΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΎΡΠ΄Π΅Π»Π΅Π½ΠΈΠΉ ΡΡΠ°ΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΈΡ
ΠΎΡΠ΅ΡΠ°ΠΏΠ΅Π²ΡΠ°
A case-control study of GST polymorphisms and arsenic related skin lesions
BACKGROUND: Polymorphisms in GSTT1, GSTM1 and GSTP1 impact detoxification of carcinogens by GSTs and have been reported to increase susceptibility to environmentally related health outcomes. Individual factors in arsenic biotransformation may influence disease susceptibility. GST activity is involved in the metabolism of endogenous and exogenous compounds, including catalyzing the formation of arsenic-GSH conjugates. METHODS: We investigated whether polymorphisms in GSTT1, GSTP1 and GSTM1 were associated with risk of skin lesions and whether these polymorphisms modify the relationship between drinking water arsenic exposure and skin lesions in a case control study of 1200 subjects frequency matched on age and gender in community clinics in Pabna, Bangladesh in 2001β2002. RESULTS AND DISCUSSION: GSTT1 homozygous wildtype status was associated with increased odds of skin lesions compared to the null status (OR1.56 95% CI 1.10β2.19). The GSTP1 GG polymorphism was associated with greater odds of skin lesions compared to GSTP1 AA, (OR 1.86 (95%CI 1.15β3.00). No evidence of effect modification by GSTT1, GSTM1 or GSTP1 polymorphisms on the association between arsenic exposure and skin lesions was detected. CONCLUSION: GSTT1 wildtype and GSTP1 GG are associated with increased risk of skin lesions
Interleukin-6 promoter polymorphism interacts with pain and life stress influencing depression phenotypes
Interleukin-6 (IL-6) has emerged as a potent biomarker for depression as its elevated plasma levels in patients with clinical depression have been confirmed by meta-analyses. Increased plasma IL-6 concentration was associated with various psychological stress factors and physical disorders accompanied by pain. Another modulator of the IL-6 level is rs1800795, a promoter polymorphism in the IL-6 gene which is able to influence its expression rate. Therefore, we examined in a Hungarian population sample of 1053 volunteers with European origins if rs1800795 polymorphism can affect depression symptoms measured by Zung Self-rating Depression Scale (ZSDS), and Brief Symptom Inventory (BSI). We also investigated the interactions of the polymorphism with reported painful physical conditions and Recent Negative Life Events (RLE) measured by the List of Life Threatening Experiences. Rs1800795 significantly interacted with both RLE and painful condition on depressive symptoms measured by ZSDS and BSI using different heritability models, while no main effects of the polymorphism were identified. After correction for multiple testing only the rs1800795 x RLE interaction effect (recessive model) remained significant on the BSI score, while both RLE and painful conditions significantly interacted on the ZSDS. In conclusion, the functional IL-6 rs1800795 polymorphism in interaction with various stress factors increases the risk of depression and has a greater impact on symptoms measured by the ZSDS. Thus, IL-6 and other cytokines may be more relevant in the development of somatic symptoms compared to affective signs of depression, delineating a specific genotype-phenotype relationship in this heterogeneous disorder
Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia
<p>Abstract</p> <p>Background</p> <p>Whereas the complement system alterations contribute to schizophrenia, complement receptors and regulators are little studied. We investigated complement receptor type 1 (CR1) expression on blood cells, the levels of circulating immune complexes (CIC) containing ligands of CR1, C1q complement protein and fragments of C3 complement protein (C1q-CIC, C3d-CIC), and CR1 C5507G functional polymorphism in schizophrenia patients and controls.</p> <p>Results</p> <p>We found an increased C1q-CIC level and CR1 expression on blood cells, elevated number of CR1 positive erythrocytes and reduced number of CR1 positive lymphocytes and monocytes in patients compared to controls. No difference in the levels of C3d-CIC between groups was observed. Higher CR1 expression on erythrocytes in CC genotype versus CG+GG for both groups was detected, whereas no difference was observed for other cell populations. Our results indicated that schizophrenia is associated with the increased CR1 expression and C1q-CIC level.</p> <p>Conclusions</p> <p>Our study for the first time indicated that schizophrenia is associated with the increased CR1 expression and C1q-CIC level. Further studies in other ethnic groups are needed to replicate these findings.</p
- β¦